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Background: Current guidelines for dosing of anti-TB drugs in children advocate higher doses for rifampicin and
isoniazid despite limited availability of paediatric data on the pharmacokinetics of these drugs, especially from
Africa, where the burden of childhood disease remains high.
Methods: Thirty children aged 6 months to 15 years underwent intensive pharmacokinetic sampling for first-line
anti-TB drugs at Queen Elizabeth Central Hospital, Blantyre, Malawi. Rifampicin, isoniazid, pyrazinamide and eth-
ambutol were dosed at 10, 5, 25 and 20 mg/kg, respectively. Plasma drug concentrations were determined using
sensitive, validated bioanalytical methods and summary pharmacokinetic parameters were estimated using
non-compartmental analysis.
Results: The median (IQR) Cmax was 2.90 (2.08–3.43), 3.37 (2.55–4.59), 34.60 (32.30–40.90) and 1.20 (0.85–
1.68) mg/L while the median (IQR) AUC0–1 was 16.92 (11.10–22.74), 11.48 (7.35–18.93), 333.50 (279.50–487.2)
and 8.65 (5.96–11.47) mg.h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively. For all drugs,
pharmacokinetic parameters relating to drug absorption and exposure were lower than those published for adults,
though similar to existing paediatric data from sub-Saharan Africa. Weight and/or dose predicted at least onemeas-
ure of exposure for all drugs. Age-related decreases in CL/F for rifampicin and pyrazinamide and a biphasic elimination
pattern of isoniazid were observed. Predicted AUC0–1 for rifampicin dosed at 15 mg/kg was comparable to that of
adults while the dose required to achieve ethambutol exposure similar to that in adults was 55 mg/kg or higher.
Conclusions: These data support recently revisedWHO recommendations for dosing of anti-TB drugs in children,
but dosing of ethambutol in children also appears inadequate by comparison with adult pharmacokinetic data.
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Introduction
Clinical diagnosis and treatment of childhood TB is challenging,
particularly in resource-poor settings where the burden of disease
is highest.1 Consequently much of the evidence supporting treat-
ment of paediatric TB is derived from clinical trials of interventions
in adults. Appropriate paediatric investigation plans were not car-
ried out for existing first-line anti-TB drugs2 and dosing recom-
mendations have been derived from schedules employed for
adults, with a relative lack of supportive data on efficacy or
safety.3–5 In 2010, on the basis of limited existing pharmacoki-
netic (PK) studies, the WHO recommended that weight-based
doses for rifampicin and isoniazid in children should be increased.6
However, there remains a paucity of reliable data on the PK of
these drugs in children. The current literature relating to first-line
drugs in the treatment of active disease from sub-Saharan Africa
comprises data from only 133 South African and 45 Malawian
children.7–12 Furthermore, most of these studies employed rela-
tively sparse sampling schemes, did not include data for all of
the first-line drugs deployed in the regimens studied and pre-
sented only descriptive analyses. Only a single small study has
subsequently reported data on PK associated with the revised
WHO recommendations.13 We report the results of a PK study
employing intensive sampling at steady-state in children repre-
sentative of the spectrum of paediatric TB in Blantyre, Malawi,
including those with HIV coinfection and malnutrition.
Methods
Clinical protocol
Children were recruited from the Department of Paediatrics at Queen
Elizabeth Central Hospital, Blantyre from January 2007 to February
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2008. All parents or guardians gave written informed consent for study
procedures. The study protocol was approved by the Ethics Committee
of the College of Medicine of the University of Malawi. Childrenwere eligible
if they were aged between 6 months and 15 years and had been com-
menced on treatment for TB as inpatients or outpatients. Baseline evalu-
ation included TB contact history and Mantoux testing using 0.1 mL of
tuberculin PPD RT23 (1:1000), read between 48 and 72 h. Induration of
10 mm or more (or 6 mm or more in an HIV-infected child) was regarded
as positive. Chest radiographs were considered suggestive of pulmonary
TB in the presence ofmediastinal adenopathy, perihilar adenopathyor per-
sistent lobar consolidation. The diagnosis of tuberculous meningitis was
accepted with appropriate CSF changes in addition to clinical signs.
Following counselling, HIV status was determined by enzyme-linked
immunoassay using HIV DETERMINE (Invernos Med, Japan Co Ltd) and
confirmed by a second assay with UNIGOLD (Trinity Biotech PK Ireland).
CD4 counts were determined for HIV-infected children. Body mass (kg)
and height (m) were measured by standard anthropometric methods.
Classification of nutritional state was based on the Waterlow14 classifica-
tion of weight for height:.90% was taken as normal; 81%–90% as mild;
70%–80%asmoderate; and,70%as severewasting. Haematocrits were
assessed and children with values,25% were not enrolled. Other labora-
tory tests performed included tests for serum alanine transferase and
creatinine.
All the children were recruited at least 2 weeks after initiation of the
intensive phase of treatment and received fixed-dose combinations
(FDCs) of anti-TB drugs approved by the National TB Programme. Each
FDC tablet or sachet contained 60 mg of rifampicin, 30 mg of isoniazid
and 150 mg of pyrazinamide, supplemented by loose 100 mg tablets of
ethambutol. Doses were administered orally once daily within the follow-
ing weight bands:,7 kg, 1 tablet; 8–9 kg, 1.5 tablets; 10–14 kg, 2 tablets;
15–19 kg, 3 tablets; 20–24 kg, 4 tablets; and 25–29 kg, 5 tablets. This
schedule corresponds to the weight-based doses recommended by the
national programme at the time of the study: isoniazid, 5 mg/kg; rifampi-
cin, 10 mg/kg; pyrazinamide, 25 mg/kg; and ethambutol, 20 mg/kg.
Children with tuberculous meningitis received intramuscular streptomycin
instead of ethambutol.
PK samplingwas performed at the hospital at least 2 weeks after treat-
ment initiation. Dosing was administered under observation by ward nurs-
ing staff with no restrictions on access to food and water. An intravenous
cannula was inserted andmaintained using heparin–saline flushes. Blood
samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8 and 24 h into lithium hep-
arin tubes, centrifuged immediately and the separated plasma frozen at
2708C until bioanalysis was performed.
Bioanalytical methods
Rifampicin and pyrazinamide plasma concentrations were determined
using HPLC on a Shimadzu LC 2010 HT system (Shimadzu, Manchester,
UK). Isoniazid and ethambutol concentrations were determined simultan-
eously using LC-MS/MS on a triple-quadrupole TSQ Quantum Access mass
spectrometer (Thermo Scientific, Hemel Hempstead, UK). All methods
incorporated appropriate internal standards and were validated to inter-
nationally recognized acceptance criteria. The lower limits of quantifica-
tion for the assays were 0.5, 2.5, 0.020 and 0.010 mg/L for rifampicin,
pyrazinamide, isoniazid and ethambutol, respectively. Full details of the
bioanalytical methods are contained in the supplementary methods
(available as Supplementary data at JAC Online).
Statistical analysis
Non-compartmental PK analysis of plasma concentration–time data was
performed using Kinetica 4.1.1 (Adept Scientific Ltd, Armor Way,
Letchworth Garden City, UK) using the trapezoidal rule with the log up–
linear down option and manual adjustment of the range of included
timepoints. Data summaries, graphics and analysis of variance of the
summary PK parameters were performed in R 2.14.1 (R Foundation for
Statistical Computing, Vienna, Austria). Analysis of variance was per-
formed with log-transformed PK parameters where appropriate and
model assumptions checked using routine graphical diagnostics.
Generalized additive models were used to evaluate continuous covariate
relationships using the packagemgcVand clustering analysis for subpopu-
lation detection in the parameter distributions was performed using the
package mclust.
Results
Table 1 shows the characteristics of children recruited into the
study. Thirty children aged between 6 months and 15 years
were enrolled with a mean age and weight of 7 years and
18 kg, respectively. Nine children were aged ,2 years and 50%
were female. The most common form of TB was pulmonary (21
patients, 70%of children), and the rest of the caseswere extrapul-
monary, including lymph node and meningeal TB. Twenty (67%)
were HIV infected. Eighteen of the HIV-infected children (90%)
were receiving co-trimoxazole prophylaxis and nine (45%) were
on ART at the time of PK sampling.
The range of actual weight-adjusted dose for each drug con-
tained in the FDC product (rifampicin, isoniazid and pyrazinamide)
and the loose ethambutol tablets is presented in Figure 1. The
Table 1. Study population (N¼30)
Age (months), median (range) 90 (7–187)
Male, n (%) 15 (50)
HIV positive, n (%) 20 (67)
Weight (kg), median (range) 18 (4.8–45)
Height (m), median (range) 102 (60–150)
Pulmonary TB, n (%) 21 (70)
Co-trimoxazole prophylaxis, n (%) 18 (60)
ART, n (%) 9 (30)
Bodyweight (kg)
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Figure 1. Weight-adjusted dose by weight band for the four drugs in
two different formulations. PZA, pyrazinamide; ETH, ethambutol; RIF,
rifampicin; INH, isoniazid.
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recommended weight-banding controls the weight-adjusted
dose within a narrow proportional range for each drug, although
the absolute range ofmg/kg dose increased with dose. Hence, the
absolute range was largest for pyrazinamide (almost 10 mg/kg
across each weight band) and smallest for isoniazid (,2 mg/kg
across each weight band). Three children received a similar
weight-adjusted dose using the adult formulations of the drugs.
Plasma concentrations for each of the drugs over time are
summarized in Figure 2. Summary PK parameters derived from
non-compartmental analysis are summarized in Table 2. Owing
to data below the limit of quantification (LOQ) of the PK assay
or a non-credible PK profile, parameters of rifampicin, isoniazid,
pyrazinamide and ethambutol could only be estimated for 28,
30, 29 and 28 of the children withmean percentage extrapolation
of the AUC0–1 of 28.6%, 3.2%, 30.8% and 10.9%, respectively;
54.4%, 11.1%, 21.1% and 10.3% of datapoints for rifampicin, iso-
niazid, pyrazinamide and ethambutol, respectively, were below
the LOQ and were omitted from the analysis. Estimates of the
apparent terminal elimination half-life were based on at least
three observations with means of 3.8, 3.6, 3.7 and 3.6 for the
four drugs, respectively.
The mean weight-adjusted dose of rifampicin received was
9.92 mg/kg with a median observed Cmax of 2.90 mg/L and an
AUC0–1 of 16.92 mg.h/L (adult reference IQR: 4.2–9.4 and
16.6–36, respectively14). Some 87% and 70% of children were
below the lower quartile for Cmax and AUC0–1, respectively, in
adults. Only 4 of 30 children exceeded the threshold of 4 mg/L
cited in adults as representing ‘very low’ exposure to rifampicin.
Of note, in eight children absorption appeared to be delayed
with a Tmax of 4 h or greater. Mean Cmax in children with delayed
absorption was lower than in those with early absorption (2.38
versus 3.58 mg/L), although this was not a statistically significant
finding (t-test P¼0.07). In multivariate analysis, AUC0–1was
related to weight-adjusted dose, increasing by 0.12 mg.h/L for
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Figure 2. Summary semi-logarithmic scatterplots of plasma concentrations of anti-TB drugs. Continuous lines represent median concentrations and
broken lines represent upper and lower quartiles.
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each additional mg/kg (P¼0.028). This was not true for Cmax,
possibly because of the delayed absorption observed in some
children. CL/F of rifampicin decreased with weight, weight-for-
height, age and co-administration of co-trimoxazole in univariate
analysis, although only weight remained significant in multivari-
ate analysis. In a generalized additive model CL/F decreased
steadily with age after a threshold of 4 years, a trend also
observed for the highly correlated weight and weight-for-height
variables (Figure 3a). Median CL/F for children under 5 years of
age was 9.76 L/h, but 4.78 L/h for children over 5 years of age,
although this was not a statistically significant difference
(Wilcoxon test P¼0.41).
The mean weight-adjusted dose of isoniazid was 5.18 mg/kg.
The median observed Cmax at 2 h was 3.37 mg/L and the AUC0–1
was 11.48 mg.h/L (adult reference IQR: 4.9–8.7 and 22.5–42.4,
respectively14). Some 80% and 90% of children were below
the lower quartile for Cmax and AUC0–1, respectively, in adults.
AUC0–1 did not increase with absolute or weight-adjusted dose
(P¼0.862 and 0.147). The rate of absorption as represented by
Tmax increased with both absolute and weight-adjusted dose
(P¼0.032 and 0.041). The overall median half-life of isoniazid
was 3.54 h, but, as expected, clustering analysis separated the
children into two main groups with mean half-lives of 1.54 h
(19.9%, likely fast acetylators) and 3.85 h (80.1%, likely inter-
mediate or slow acetylators) (Figure 3b). Of note, 18 of 30 children
had detectable concentrations of isoniazid at 24 h post-dose, a
finding highly suggestive of biphasic elimination. Re-analysis
omitting this timepoint was performed to examine the influence
of this information and showed that the overall median half-life
would have been estimated at 1.65 h, a figure more similar to
many previous reports, with a similar predicted proportion of
fast acetylators.
The mean weight-adjusted dose of pyrazinamide was
24.80 mg/kg. The median observed Cmax at 2 h was 34.6 mg/L
and the AUC0–1 was 333.50 mg.h/L (adult reference IQR: 46.0–
61.4 and 406.2–632.3, respectively14). Some 83% and 67% of
childrenwere below the lower quartile for Cmax andAUC0–1, respect-
ively, in adults. Cmax was significantly related to absolute dose
(P¼0.02), but AUC0–1was not (P¼0.11). The Tmax of pyrazinamide
increased with absolute dose (P¼0.049). The CL/F of pyrazinamide
appeared to decrease significantly with age (P¼0.036) and this
trend appeared linear in a generalized additive model.
Themeanweight-adjusted dose of ethambutolwas 17.05 mg/kg.
Themedian observed Cmax at 2 h was 1.2 mg/L and the AUC0–1was
8.65 mg.h/L (adult reference IQR: 4.1–6.3 and 19.2–30.8, respect-
ively14). Some100%and 93%of childrenwere below the lower quar-
tile for Cmax and AUC0–1, respectively, in adults. Cmax, AUClast and
AUC0–1 were all strongly predicted by absolute, but not weight-
adjusted, dose with AUC0–1 increasing by 0.13 mg.h/L for each
additional milligram. Age also appeared to affect measures of
exposure with AUC0–1 increasing by 0.013 mg.h/L for each add-
itional month of age. Serum creatinine was also a significant
predictor for AUC0–1 with exposure increasing by 8.649 mg.h/L
for each additional g/dL (P¼0.048). Ethambutol exhibited a very
high apparent volume of distribution (333 L or 18.5 L/kg).
HIVcoinfectionwas not associatedwith any significant change
in PK parameters.
Co-administration of co-trimoxazole prophylaxis appeared to
increase the CL/F of rifampicin alone (P¼0.028), while concomi-
tant ART did not impact any PK parameter. Weight-for-height
was not identified as an important covariate for any of the
drugs or parameters.
Given the complex relationships observed with dose and weight
and lack of information on NAT2 genotype, it was only possible to
cautiously evaluate alternative dosing recommendations for rifam-
picin and ethambutol. For rifampicin, assuming a linear relationship
with weight-adjusted dose, the expected AUC0–1 at the newly
recommended target of 15 mg/kg would be 65.1 mg.h/L, which
exceeds the upper quartile of the observed adult range. For etham-
butol, however, linearextrapolation of averageweight-adjusteddose
suggested that an AUC0–1 comparable to adults (.19.2 mg.h/L)
could only be achieved at a dose of 55 mg/kg or higher.
Discussion
This study is the most intensive PK study of all four first-line
anti-TB drugs yet undertaken in children with TB and adds sub-
stantially to the evidence available, especially in sub-Saharan
Table 2. Summary PK parameters derived from non-compartmental analysis
Rifampicin (n¼28) Isoniazid (n¼30) Pyrazinamide (n¼29) Ethambutol (n¼28)
Cmax (mg/L) 2.90 (2.08–3.43) 3.37 (2.55–4.59) 34.60 (32.30–40.90) 1.20 (0.85–1.68)
Tmax (h) 2.00 (1.00–4.00) 2.00 (1.00–2.75) 2.00 (1.00–3.00) 3.00 (2.00–4.00)
AUC0–last (mg.h/L) 7.50 (5.59–13.06) 11.21 (7.03–18.40) 194.70 (163.40–382.40) 8.00 (4.92–10.07)
AUC0–1 (mg.h/L) 16.92 (11.10–22.74)
a 11.48 (7.35–18.93)b 333.50 (279.50–487.2) 8.65 (5.96–11.47)
t1/2 (h) 2.01 (1.64–3.27) 3.54 (2.95–4.50) 5.64 (4.47–6.81) 6.49 (5.69–8.04)
CL/F (L/h) 5.41 (3.38–10.64) 5.67 (4.34–8.27) 0.75 (0.48–1.16) 34.0 (19–43)
Vz/F (L) 20.840 (14.850–43.060) 28.93 (21.6–42.9) 6.193 (3.691–9.334) 289 (207–410)
Vss/F (L) 33.040 (20.10–49.790) 28.3 (19.2–34.8) 7.642 (4.205–10.280) 333 (229–413)
Cmax, maximum observed plasma concentration; Tmax, time of maximum observed plasma concentration; AUC0-last, area under the curve to last
observed plasma concentration; AUC0-1, area under the curve extrapolated to infinity; t1/2, apparent elimination half-life; CL/F, apparent clearance;
Vz/F, volume of distribution; Vss/F, volume of distribution at steady-state.
Data are presented as median (IQR).
aBased on 17 subjects.
bBased on 28 subjects.
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Africa, which bears the highest burden of childhood disease. All
studies of African children have to date been performed in
South Africa,7 – 11 with the exception of a single study from
Malawi, which evaluated intermittent dosing of pyrazinamide
and ethambutol alone.12 The size of the cohort, nine-point sam-
pling strategy and sensitive bioanalytical methods adopted in the
current study allowed for more accurate and precise estimates of
PK parameters using non-compartmental techniques than was
previously possible, particularly Cmax, which may be underesti-
mated by sparse sampling. More importantly, improved estimates
of AUC0–1, believed to be the key determinant of clinical efficacy
for most first-line drugs, could also be obtained.
The most important measures of absorption and exposure
(Cmax and AUC0–1) for all of the drugs assayed in this representa-
tive group of African children with TB were lower than typically
observed in African adults using the same analytical approach.15
For most drugs, some relationship of exposure with absolute or
less commonly weight-adjusted dose was observed for at least
onemeasure of exposure. In addition, for rifampicin and pyrazina-
mide, there appeared to be an independent relationship of CL/F
with age. Isoniazid elimination appeared biphasic, with a longer
apparent half-life than previously reported, but a frequency of
fast acetylator phenotype similar to reports from South Africa.
This finding probably resulted from the availability of a sample
at 24 h and the highly sensitive bioanalytical method used for iso-
niazid. Although observed in some previous studies, the possible
metabolic basis of this finding is currently unknown. Exposure of
ethambutol appeared to be significantly related to creatinine.
Neither HIV nor nutritional status significantly affected the PK
parameters of any of the drugs. Co-administration of ART or
co-trimoxazole prophylaxis also did not appear to have any
impact with the possible exception of a small increase in rifampi-
cin CL/F associated with co-trimoxazole co-administration.
These findings are generally in agreement with limited data
available from elsewhere in Africa and support recent recommen-
dations by the WHO to increase the dose of isoniazid and rifampi-
cin in children with TB to 10 and 15 mg/kg, respectively. Although
PK targets for treatment success in TB are not well-defined, ensur-
ing exposure in children at least equivalent to adults is logical
given the excellent overall performance of first-line therapy in
adults. The data presented here might also suggest that dose
modification could be considered for pyrazinamide and etham-
butol. However, it was difficult to accurately predict the equivalent
doses required due to sometimes complex relationships observed
between dose, weight and the PK parameters. This may be
attributable to the relatively small sample size and in the case
of isoniazid to tight weight-banding in a small dose range and
confounding effects of acetylator status. Absolute dose size did
appear to independently predict exposure of pyrazinamide and
ethambutol, however. In the case of ethambutol, extrapolation
of this relationship with AUC0–1 appeared to confirm previous
suggestions that current dosing of ethambutol in children may
be inadequate and that a substantial dose increase would be
needed to achieve plasma concentrations comparable to those
in adults. This finding is consistent with the results of a previous
study in Blantyre, which evaluated thrice weekly dosing at
35 mg/kg, achieving a Cmax of only 1.8 mg/L. These extrapolations
assume linearity of PK at higher doses and better predictions
might be obtained using a more sophisticated modelling
approach and dose-ranging data. A single small study from
South Africa has also suggested that the new dosing recommen-
dations can achieve the targeted exposures desired.13
In addition to relationships observed with dose and weight,
other features relating to the metabolism of certain drugs were
observed. Using empirical clustering, an unequivocally fast acety-
lator phenotype could be attributed to 20% of the children, con-
sistent with previous studies in South Africa, which reported a
homozygous slow acetylator NAT2 genotype in 36%–40% of chil-
dren.8,10,13However, the African region exhibits the greatest diver-
sity at this locusworldwide16,17and further characterization of the
distribution of NAT2 alleles in Malawi would be useful in view of
the prolonged half-life of isoniazid that was observed. Both rifam-
picin and pyrazinamide appeared to exhibit age-related changes
in CL/F independent of body size that were judged statistically sig-
nificant. For pyrazinamide this trend appeared linear over the age
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range studied, whereas for rifampicin CL/F appeared to decrease
around 4 years, ultimately halving over the age range. These
changes may reflect the greater relative liver size and blood
flow per kilogram in younger children.18 Why the shape of
these trends should differ is unclear, although it might reflect
maturation processes specific to the dominant metabolic path-
ways for the two drugs (hepatic carboxyesterases for rifampicin
and amidase for pyrazinamide). The apparent CL/F of pyrazina-
mide reported here is lower than that observed in adults, but
this could reflect changes in bioavailability relative to adults rather
than truly reduced clearance, given the sachet formulation used
in this study. Ethambutol exposure was related to serum creatin-
ine, which is consistent with the renal route of elimination of the
drug. CL/F was not clearly related to serum creatinine, but this
may be due to the restricted range of the covariate in this dataset.
From a clinical perspective the study provides insight into dos-
ing in potentially important subgroups and with other commonly
co-administered medications. We found no evidence that HIV or
nutritional status significantly affected PK parameters or that
there are any important PK interactions with co-trimoxazole
prophylaxis or nevirapine-based ART. Although the analysis
suggested a possible increase in CL/F of rifampicin with
co-administration of co-trimoxazole prophylaxis, this has not
been reported elsewhere and could be a chance finding requiring
independent confirmation. Overall, these data provide reassur-
ance that dosage adjustment of anti-TB drugs is not needed for
any of these specific reasons. However, it should be noted that
the study was not designed to evaluate different phenotypes of
malnutrition and further work would be necessary to substantiate
this conclusion.
In conclusion, this intensive PK study demonstrates that
plasma exposures of first-line anti-TB drugs in Malawian children
are lower than those observed in African adults, confirming the
limited data available to date from paediatric PK studies in the
region. These findings are supportive of recent WHO recommen-
dations to increase the doses of rifampicin and isoniazid in routine
paediatric practice, but the low exposures of ethambutol
observed also suggest that the dose and role of this drug in child-
hood TB should be revisited.
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